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The development of a novel comprehensive approach for the prediction of hERG
activity is herein presented. Software Phase has been used to derive a 3D-QSAR
model, employing as alignment rule a common pharmacophore built on a subset of 22
highly active compounds (threshold Ki: 50 nM) against hERG K+ channel. Five features
comprised the pharmacophore: two aromatic rings (R1 and R2), one hydrogen-bond
acceptor (A), one hydrophobic site (H), and one positive ionizable function (P). The
sequential 3D-QSAR model developed with a set of 421 compounds (randomly divided
in training and test set) yielded a test set (Q2) = 0.802 and proved to be predictive with
respect to an external test set of 309 compounds that were not used to generate the
model (r2ext_ts = 0.860). Furthermore, the model was submitted to an in silico validation
for assessing the reliability of the approach, by applying a decoys set, evaluating the
Güner and Henry score (GH) and the Enrichment Factor (EF ), and by using the ROC curve
analysis. The outcome demonstrated the high predictive power of the inclusive 3D-QSAR
model developed for the hERG K+ channel blockers, confirming the fundamental validity
of the chosen approach for obtaining a fast proprietary cardiotoxicity predictive tool to be
employed for rationally designing compounds with reduced hERG K+ channel activity at
the early steps of the drug discovery trajectory.
Keywords: 3D-QSAR, pharmacophore modeling, ligand-based model, human Ether-à-go-go-related gene (hERG),
cardiotoxicity
INTRODUCTION
The hERG K+ channel is a member of the Ether-à-go-go family encoded by KCNH2
gene that consists of four identical subunits (Trudeau et al., 1995). This channel is well
known for its important role in the electrical activity of the heart that coordinates heart’s
beating. Mutations in KCHN2 gene lead to long-QT syndrome, which can lead to ventricular
arrhythmia or other adverse effects on cardiovascular system, causing sudden death (Sanguinetti
et al., 1995; De Bruin et al., 2005; Sanguinetti and Tristani-Firouzi, 2006). hERG K+
channels are particularly sensitive to blockage by a large number of structurally diverse
drugs and are critical antitargets in drug discovery process (Dumaine and Kirsch, 1998;
Dumaine et al., 1998; Barbey et al., 2002; Redfern et al., 2003; Thomas et al., 2003a,b;
Rajamani et al., 2006). The interaction of small molecules with hERG K+ channel is one
of the major issues encountered by the pharmaceutical companies related to the drug
development process. Blockade of hERG K+ channel has then become a severe limitation for
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the introduction of new drugs in the market. Moreover, in
the recent years several blockbuster drugs including astemizole,
droperidol, terfenadine, lidolazine, sertindole, cisapride, and
chlorpromazine have been discontinued due to their relevant
activity on hERG K+ channel (Honig et al., 1993; Mohammad
et al., 1997; Gottlieb, 1999; Barbey et al., 2002; Ray et al.,
2004; Roden, 2004). Currently, pharmaceutical companies
may account on high throughput methods for predicting
the capability of compounds to interfere with hERG K+
channels, thus identifying safer compounds at the early stage
of the drug discovery process. However, the inherent costs
associated to this screening procedure are dramatically elevated
in terms of expenditure, amount of molecules consumed,
and time of analysis. Accordingly, the development of a
fast and reliable computational procedure for an early and
trustworthy prediction of hERG K+ channel interference would
represent a useful and significant advance in this frame.
Recently, for this purpose diverse ligand-based computational
models have been developed (see ref Keserü, 2003; Aronov,
2005; Wang et al., 2013, 2016; Braga et al., 2015 for further
details). Moreover, three dimensional (3D) channel models using
homology modeling technique were generated and adopted in
molecular docking/molecular dynamics simulations for an in
silico assessment of potential affinity of compounds for hERG
K+ channel (Farid et al., 2006; Boukharta et al., 2011; Durdagi
et al., 2011, 2012; Dempsey et al., 2014). This latter approach
was successfully applied by us in the past for investigating
hERG affinity of a class of antimalarials (Gemma et al., 2012)
and antipsychotics agents (Butini et al., 2009, 2010; Brindisi
et al., 2014). However, despite its accuracy, this approach is
extremely time consuming. So, adopting a protocol based on
homology model, molecular docking, and molecular dynamics is
a challenging task for studying a large number of compounds.
To improve accuracy of investigation of large set of molecules,
we have developed and validated an inclusive 3D-QSAR model
aimed at obtaining a fast predictive in silico tool able to
unveil potential hERG K+ channel activity of structurally
diverse blockers at the early stages of our drug discovery and
development process. This tool could be of pivotal importance
for assisting us and others in designing active compounds for a
given target endowed with limited hERG K+ channel affinity.
RESULTS AND DISCUSSION
We have recently reported a series of predictive 3D-QSAR
studies for different targets, in which a Phase common features
pharmacophore has been used as the alignment rule for deriving
quantitative structure-activity relationship models. These latter
were used in virtual screening protocols and for rationally
designing a library of compounds active on a given target (Brogi
et al., 2011, 2013, 2015, 2016; Castelli et al., 2012; Pasquini
et al., 2012; Zaccagnini et al., 2017). The results of the above-
mentioned drug discovery investigations inspired us to generate
a comprehensive computational model for predicting potential
hERG-related cardiotoxicity of compounds during the early steps
of the drug discovery process employing the same software. For
this purpose, a data set of 421 compounds (see the Supplementary
Material for further details and references) with hERG K+
channel binding affinity spanning five orders of magnitude (from
3.3 nM of compound 1 to 54 µM of compound 421, Table
S1) and belonging to different structural classes, were used for
deriving a predictive hERG 3D-QSAR model. Among them, 22
compounds selected from the literature (1–22, Figure 1, Table
S1) as potent hERG K+ channel blockers such as astemizole (1)
(Finlayson et al., 2001; Fletcher et al., 2002; Blackburn et al.,
2006; Murphy et al., 2006; Zhu et al., 2006; Deacon et al., 2007;
Coon et al., 2009; Owen et al., 2009; Patel et al., 2009; Liu et al.,
2010; Aspiotis et al., 2011; Levoin et al., 2011) were chosen
for developing a common features pharmacophore (Figure 2),
subsequently used as alignment rule for generating the 3D-QSAR
model. At this step the compounds were randomly divided, 60%
in the training and 40% in the test set (Table S1). This choice
was made to guarantee the inclusion of the positive information
arising from 60% of the compounds included in the training
set (corresponding to 253 compounds), for the development of
the computational tool. At the same time the high number of
compounds kept in the test set (40%, 168 compounds) assures an
appropriate evaluation of the predictive power of the generated
model by means of an exhaustive internal cross-validation.
Remarkably, for reducing the weakness of the ligand-based
approach, an extensive conformational analysis for the selected
ligands was accomplished by means of MacroModel software
(see experimental section for further details). Conformational
analysis is relevant for enhancing the quality of the alignment for
the compounds used to build the 3D-QSAR model as well as the
consistency of the in silico tool (Brogi et al., 2011, 2013, 2015;
Durdagi et al., 2011; Zaccagnini et al., 2017).
The top-ranked hypothesis (AHPRR.42), obtained by means
of Phase, was formed by five features: two aromatic rings (R1
and R2), one hydrogen-bond acceptor (A), one hydrophobic site
(H), and one positive ionizable function (P). Pharmacophore
AHPRR (shown in Figure 2A superimposed to astemizole (1),
its inter-feature distances are reported in Figure 2B) highlighted
the structural requirements for interacting with the channel,
as confirmed by the comparison between the docked pose of
astemizole (1) into hERG K+ channel homology model (Masetti
et al., 2008) with the alignment of 1 onto the pharmacophore
model. Moreover, the analysis with molecular determinants
reported by Farid and co-workers for a large number of
hERG blockers is consistent with our developed computational
model (Farid et al., 2006). Accordingly, it could be inferred
that pharmacophore AHPRR actually accounts for relevant
interactions between selected molecules and hERG channel.
Indeed, it is well known that pi-pi stacking or hydrophobic
contacts with key residues of hERG K+ channel such as
Y652 and/or F656 as well as ionic interactions are commonly
found for a large number of hERG blockers. In fact, positively
charged functional groups are present in many drugs that
strongly bind hERG K+ channels. The presence of atoms
able to form polar contacts with T623 and S624 represents
another important requirement for hERG inhibition. Therefore,
the above-mentioned AHPRR hypothesis accounts for the key
features, which play a pivotal role for hERG K+ channel affinity,
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FIGURE 1 | Structure of highly active compounds against hERG K+ channel used for generating a common features pharmacophore.
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FIGURE 2 | (A) Superposition of highly active compound 1 (astemizole) and
AHPRR hypothesis. (B) AHPRR hypothesis and its inter-feature distances.
Features are as follows: H-bond acceptors = A, red vector; hydrophobic
feature = H, green sphere; positive ionizable = P, blue sphere; aromatic
feature = R1 and R2, orange rings (the pictures were generated by means of
Maestro software).
when at appropriate reciprocal distances. Consequently, it is
not arbitrary to state that matching the pharmacophore may be
predictive for binding to the channel. The AHPRR hypothesis
was then used to align the molecules for the development of
an atom-based 3D-QSAR model. As suggested by the Phase’s
user manual, the atom-based version of Phase’s 3D-QSAR
workflow was preferred to the pharmacophore-based one. Such
a choice implied considering the whole contributions to hERG
channel activity as deriving from all the structural features also
including the steric clashes, rather than from only those from the
pharmacophore relevant features.
Models containing one to seven partial least squares (PLS)
factors were generated, whose statistical parameters are detailed
in Table 1. The model featuring seven PLS factors was chosen,
since it better performed on the whole than those with fewer PLS
factors. We have considered models containing up to seven PLS
factors to avoid over-fitting phenomena. The high correlation
and cross-validated correlation coefficients (r2 = 0.911 and
Q2 = 0.802, respectively) of the selected model together with
the high Pearson R-value (R-Pearson = 0.901), suggested a
close correspondence between estimated and experimental Ki-
values. These parameters are indicative of a computational model
characterized by a strong predictive power and significance.
A scatter plot of experimental against predicted activities was
built to assess the results (Figure 3), which showed that Ki-values
were effectively estimated for compounds belonging to training
and test sets (Table S1). This latter, coupled with the limited
number of PLS factors, the small RMSE-value, standard deviation
(SD), variance ratio (P), and the large F-value supported the
reliability of the approach.
3D plots of the crucial volume elements occupied by ligands
were employed to visualize the outcome of the 3D-QSAR
model. In Figure 4 is depicted the 3D plot representation of
the model superimposed to high (1, 2, 3, and 13), moderate
(35, 56, 398, and 409), and less active derivatives (54, 57, 75,
and 421; Figures 4A–N, respectively). In this illustration, the
cubes represent positive (blue cubes) and negative (red cubes)
coefficients. For a ligand possessing atoms or functional groups
occupying these volumes an increase or a decrease of activity
TABLE 1 | 3D-QSAR statistical parameters of the seven Phase-derived
sets of models.
PLS r2a SDb Fc Pd RMSEe Q2f R-Pearsong
1 0.179 0.793 54.7 2.13e-12 0.532 0.382 0.647
2 0.387 0.687 78.8 2.94e-27 0.470 0.518 0.738
3 0.574 0.573 112.0 6.40e-46 0.469 0.521 0.763
4 0.737 0.452 173.4 1.31e-70 0.382 0.681 0.829
5 0.831 0.363 242.8 3.65e-93 0.338 0.751 0.868
6 0.872 0.316 279.6 8.18e-107 0.327 0.767 0.883
7 0.911 0.264 357.9 9.14e-125 0.301 0.802 0.901
ar2, value of r2 of the regression.
bSD, standard deviation of the regression.
cF, variance ratio.
dP, significance level of variance ratio.
eRMSE, root-mean-square error.
fQ2: value of Q2 for the predicted activities.
gR: r-Pearson, correlation between the predicted and observed selectivity index values
for the test set.
FIGURE 3 | Scatter plot for the predicted and observed pKi values (M)
as calculated by the 3D-QSAR model applied to the training set (blue)
and test set (cyan) compounds.
could be predicted. Notably, compound 1 as well as other highly
active molecules mainly occupy the blue regions (Figures 4A–D),
while the less active compounds such as 421 largely resides on the
red regions (Figures 4I–N).
After the generation of the 3D-QSAR model and, in order to
perform its theoretical validation, an external test set was selected
from the literature. This set was composed of 309 unrelated
compounds not used for generating the model, with different
inhibitory potency against hERG K+ channel (ranging from 0.28
nM to 51 µM; Table S2 in the Supplementary Material). We have
included very active compounds in order to stress the model for
assessing its actual predictive power. Satisfyingly, the activities of
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FIGURE 4 | (A–D) Superposition of highly active compounds 1 (astemizole), 2, 3, and 13 with the 3D-QSAR model. (E–H) Superposition of moderate active
compounds 35, 56 (vanoxerine GBR-12909), 398 and 409 with the 3D-QSAR model. (I–N) Superposition of less active compounds 54 (fexofenadine), 57
(ketoconazole), 75 and 421 with the 3D-QSAR model. The pictures were generated by means of Maestro software (Schrödinger, LLC, New York, NY, 2015).
the compounds included in the external test set were satisfactorily
estimated by our model (Table S2). In the scatter plot depicted
in Figure S1, the experimental and predicted pKi-values of
these compounds are also displayed (correlation coefficient r2ext_ts
= 0.860). This outcome provided further indication that the
correlation of the model was not accidental.
Furthermore, thementionedmodel was submitted to a further
in silico validation by using two different approaches. In order
to perform this step, we applied a commonly used validation
method based on the generation of decoys set. Starting from
highly active compounds used for the model generation (1–
22), other compounds with relevant potency against hERG K+
channel (cut-off Ki ≤ 150 nM; Table S1) and active molecules
from the external test set (cut-off Ki ≤ 150 nM; Table S2) for
a total of 111 actives (Table S3), we generated 7,250 decoys
by means of Database of Useful Decoys: Enhanced (DUD-E)
server (Huang et al., 2006; Mysinger et al., 2012; see Materials
and Methods section for further details about the selection of
active compounds). This procedure is largely used to assess the
ability of in silico tools such as 3D-QSAR models, to discriminate
between inactive or active derivatives (Sakkiah et al., 2011;
Thangapandian et al., 2011; Braga and Andrade, 2013; Krishna
et al., 2014; Brogi et al., 2015, 2016). Based on the obtained
results, the assessment clearly demonstrated the validity of the
proposed model. The analysis of the results (Figure 5A) of the
decoys set revealed a trend where the inactive compounds fail to
completely fulfill all the pharmacophore features, thus making
their predicted activity very poor or absent. On the contrary,
active compounds were reasonably well estimated by the 3D-
QSAR model. Notably, we have found 39 actives in the top
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FIGURE 5 | EF and GH scores obtained by the application of 3D-QSAR model in a database screening and ROC curve generated from database
screening.
fifty ranked compounds. Moreover, this qualitative analysis was
also supported by Enrichment Factor (EF) and Goodness of hit
(GH) values. The statistical parameters obtained from the model
validation were reported in Figure 5A and calculated as reported
in the Materials and Methods section.
In particular, a database of 7,361 compounds (D) including
111 known active molecules (A) was used to early validate our
hERG 3D-QSARmodel herein discussed. The database screening
results (Figure 5A) displayed that 50 molecules were found as
hits (Ht) (cutoff value corresponding to potential purchasable
compounds after a virtual screening protocol). Among Ht, 39
compounds (Ha) are known hERG blockers (A). From screening
we calculated an EF = 51.72, meaning that it could be about
52 times more probable to find active molecules from chemical-
databases with respect to chance. The estimated GH score value
of 0.67, larger than 0.5, demonstrates a great consistency of the
model, suggesting that the presented computational model could
be efficiently used for designing compounds with reduced hERG
K+ channel affinity.
The 3D-QSAR model was evaluated by means of the receiver
operating characteristic (ROC) curve, for assessing the balance
between model sensitivity and specificity (capability to discover
true positives and capability to avoid false positives, respectively;
Triballeau et al., 2005; Zhao et al., 2009; Zaccagnini et al.,
2017). Compounds included in the validation database (7,361
compounds) were virtually screened by using the generated
computational tool and ordered according to their estimated
pKi. The output of ROC curve provided a score for assessing
the performance of the model. In particular, the closer the ROC
score is to 1.0, the better is the model at discriminating active
from inactive compounds. The AUC score of our presented
in silico model was found to be 0.96 (Figure 5B), showing
high confidence of the 3D-QSAR model, indicating that the
computational tool possessed a rationale for virtual screening,
and it could be effectively used to rationally design compounds
with reduced hERG activity. Notably the performance of our
model appears to be comparable with the previous published
models (Aronov, 2005;Wang et al., 2013, 2016; Braga et al., 2015).
CONCLUSION
In summary, a pharmacophore hypothesis was built by applying
ligand-based pharmacophore generation workflow, implemented
in Phase, followed by the development and validation of a 3D-
QSAR model, by using PLS analysis for estimating the hERG K+
channel activity, using a large set of compounds (training set,
test set, and an external test set for a total of 730 molecules).
The aim of this approach was to develop a fast and reliable in-
house computational tool for the prediction of hERGK+ channel
activity during the drug discovery process. The computational
model developed and validated by us is endowed with strong
predictivity, as herein described, and might be useful for the
rational design and optimization of new inhibitors against a given
target with reduced potential hERG-related cardiotoxicity.
MATERIALS AND METHODS
Computational Details
3D-QSAR Model Generation
3D structure building, pharmacophore mapping and 3D-QSAR
studies were carried out by means of Maestro 10.1 (Schrödinger,
LLC, New York, NY, 2015). Phase 4.2 (Schrödinger, LLC, New
York, NY, 2015), implemented in Maestro suite, was used to
generate pharmacophore hypotheses and 3D-QSAR model for
hERGK+ channel. Conformers of each derivative were generated
by means of MacroModel 10.7 (Schrödinger, LLC, New York,
NY, 2015), using the OPLS_2005 force field (Jorgensen et al.,
1996). The solvent effects are simulated employing the analytical
Generalized-Born/Surface-Area (GB/SA) model (Still et al.,
1990), and no cutoff for nonbonded interactions was selected.
Polak-Ribiere conjugate gradient (PRCG) method with 2,000
maximum iterations and 0.001 gradient convergence threshold
was employed. The conformational searches were carried out by
applying MCMM (Monte Carlo Multiple Minimum) torsional
sampling method. Automatic setup with 21 kJ/mol (5.02
kcal/mol) in the energy window for saving structure and a
0.5 Å cutoff distance for redundant conformers was used.
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Phase was employed to develop common features hypotheses.
Pharmacophore feature sites for the compounds were specified
by a set of features well-defined in Phase as hydrogen-bond
donor (D), hydrogen-bond acceptor (A), aromatic ring (R),
positively charged group (P), negatively charged group (N),
and hydrophobic group (H). Twenty-two active compounds
(Figure 1 and in Table S1 in the Supplementary Material)
were selected for generating the pharmacophore hypotheses
for hERG K+ channel. Common pharmacophore hypotheses
were identified, scored and ranked by means of conformational
analysis and tree-based partitioning techniques. The best ranked
pharmacophore model obtained by Phase [AHPRR, shown in
Figure 2 superimposed to astemizole (1)], consisted of five
features: two aromatic rings (R1 and R2), one hydrogen-bond
acceptor (A), one hydrophobic site (H), and one positive
ionizable function (P). This pharmacophore was chosen for
further 3D-QSAR analysis. All molecules used for QSAR
studies (Table S1) were aligned to the selected pharmacophore
hypothesis. In this study, we set a pKi threshold for the selection
of active and inactive ligands. Compounds were chosen based
on the displacement assay against hERG using the labeled
[3H]dofetilide. In particular, compounds that showed a Ki
comprised between 5 and 54 µM were considered as inactive
compounds. Moderate inhibitors were considered compounds
with Ki between 50 nM and 5 µM, while compounds possessing
a Ki ≤ 50 nM were considered potent inhibitors of hERG
K+ channel and consequently as active in hERG blockage
during 3D-QSAR model generation, a very similar selection was
already reported in literature (Durdagi et al., 2011). Notably only
molecules with experimentally definite inhibitory potency have
been selected to develop the in silicomodel, for avoiding possible
faults arising from the inclusion in the set of molecules with
uncertain activity. Atom-based QSAR models were generated for
hERG hypothesis using the 253 compounds in the training set
(421 compounds were randomly divided 60% in the training
and 40% in the test set) and a grid spacing of 0.5 Å. QSAR
models containing one to seven PLS factors were produced, and
an internal cross-validation was achieved employing leave-n-
out (LnO) technique as specified in Phase user manual (Phase,
version 4.2, UserManual, Schrödinger press, LLC, New York, NY,
2015).
3D-QSAR Model Validation
Extensive model validation was performed using an external test
set of compounds (309 molecules) not used for generating and
cross validating the model. Compounds were prepared by using
Maestro, LigPrep and MacroModel adopting the same procedure
for preparing the molecules used to derive the model.
DUD-E web server (http://dude.docking.org access date
November 2016) was employed to generate a set of decoys
starting from the active compounds selected to develop the
pharmacophore model, other compounds with relevant activity
against hERG K+ channel and active compounds in the external
test set, for a total of 111 active compounds (Table S3).
For this set of active ligands, DUD-E server made available
7,250 inactive ligands from a subset of the ZINC database
(http://zinc.docking.org access date November 2016) filtered
by means of Lipinski rules for drug-likeness, for a total of
7,361 compounds between inactives and actives. Each of these
inactive decoys was selected to bear a resemblance to the
reference molecule in terms of physico-chemical properties but
a divergence from it in 2D structure (e. g. large difference of
Tanimoto coefficient between decoys and active compounds).
The generated decoys were divided in 145 smiles files,
downloaded from the website, imported into Maestro and
prepared by means of LigPrep 3.3 (Schrödinger, LLC, New York,
NY, 2015) to properly convert smiles into three-dimensional
structures. Subsequently, in order to perform aminimization and
a conformational search of the obtained structures MacroModel
program was adopted (the same parameters reported for ligand
preparation were applied). A single file with conformers of
active molecules and decoys was produced and submitted to the
software for evaluating the activity against hERG K+ channel
using the 3D-QSAR model employing “search for matches”
option. After decoys generation and the prediction of pKis, the
Güner and Henry score, i.e., goodness of hit-list (GH) and the
enrichment factor (EF) value were estimated using the Equations
1, 2, respectively.
EF =
Ha/Ht
(A/D)
(1)
GH =
{
Ha ∗ (3A+Ht)
4HtA
}
∗
[
1−
(Ht −Ha)
(D− A)
]
(2)
Ht represents the total number of compounds in the hit
list found by virtual screening, Ha is the total actives found
by virtual screening considering the top 50-ranked position
(positions comprise within the cutoff value). The total number
of compounds (Ht) might represent the amount of molecules to
purchase after a virtual screening protocol and almost the 1% of
the considered database (D). A represents the total of the active
derivatives enclosed in the database, and D stands for the total
number of molecules existing in the set. The GH score ranges
from 0 to 1. The GH score 0 indicates a null model; while the
GH score 1 denotes an ideal model. Additionally, by using the
equations 3 and 4, the % yield of actives (%YA) and % ratio of
actives (%RA) were calculated, respectively.
%YA =
[(
Ha
Ht
)
∗ 100
]
(3)
%RA =
[(
Ha
A
)
∗ 100
]
(4)
Enrichment Calculator (enrichment.py) script (https://www.
schrodinger.com/scriptcenter) was employed to assess the
predictive power of the 3D-QSAR model by a Receiving
Operator Curve (ROC). The mentioned script calculates the
enrichment metrics, including area under the receiver-operating
characteristic curve (AUC), from virtual screening by means of
the output structure file and a list of known active molecules.
The output of the screening protocol, employing decoys and
active molecules, consisted of a list of molecules ranked by the
predicted activity from the top-predicted molecules as estimated
by the 3D-QSARmodel. These ranking data and a list file of active
compounds were used as input for enrichment.py application.
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